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The human EGF receptor as a target for cancer therapy: six new rat
mAbs against the receptor on the breast carcinoma MDA-MB 468
H. Modjtahedi, J.M. Styles & C.J. Dean
Section ofImmunology, Institute ofCancer Research, Sutton, Surrey, UK.
Summary Using the breast carcinoma cell line MDA-MB 468 as immunogen, we have produced six new rat
monoclonal antibodies (mAbs) against the human EGF receptor (EGFR) and are investigating their use for
diagnostic and therapeutic applications in cancer patients whose tumours overexpress these receptors. The
mAbs (three IgG2b and one each of IgG2a, IgGI and IgA) were selected on the basis that they bound to the
extracellular domain of the EGFR and blocked growth factor-receptor interaction. Competitive assays showed
that, with the exception of antibody ICR65, the mAbs bound to one of two distinct epitopes on the external
domain of the EGFR. ICR65, however, cross-reacted with mAbs binding to both epitopes. All of the mAbs
immunoprecipitated the 170 kDa glycoprotein from cells expressing the EGFR but not the 185 kDa product of
the related c-erbB-2 proto-oncogene. Unlike EGF and TGFa none of the mAbs stimulated the growth of
quiescent human foreskin fibroblasts but they inhibited the EGF and TGFa induced growth stimulation of
these cells in vitro. When tested for their effect on tumour cells the mAbs were found to inhibit the growth in
vitro of a number of human tumours that overexpressed the EGFR (e.g. HN5, HN6, HN15, A431, MDA-MB
468) but they were without effect on tumour cell lines expressing low or undetectable amounts of the receptor.
Our initial results indicate that this new generation of antibodies which bind with high affinity to the EGFR,
block growth factor-receptor interaction and inhibit the growth of human squamous carcinoma cell lines
overexpressing the receptor have potential for clinical application.
Data from a number of laboratories indicate that over-
expression of the receptor (EGFR) to which EGF, TGFa
and other polypeptide hormones bind, plays an important
role in the development of certain types of human malignan-
cies (Santon et al., 1986; Ozanne et al., 1986; Velu et al.,
1987; Difore et al., 1987; Harris et al., 1990). In addition,
some of these tumours produce ligands for the receptor and
it has been suggested that an autocrine mechanism is
involved in progression of cancers of this type (Sporn &
Roberts 1985; Imanishi et al., 1988; Nistar et al., 1988;
Dernyck 1990; Tateishi et al., 1990; Yoshida et al., 1990;
Morishige et al., 1991). Over-expression of the EGFR by
tumour cells, compared to their normal counterparts, has
been reported for a number of squamous cell carcinomas
(e.g. Cowley et al., 1984; Hendler et al., 1984; Sainsbury et
al., 1985; Gullick et al., 1986) and this in turn was also
correlated to poor prognosis in patients with some of these
carcinomas (reviewed by Gullick, 1991).
The high level of expression of the EGFR on squamous
cell carcinomas and the important role of the receptor (a
170 kD transmembrane tyrosine kinase) in signal trans-
duction (Ullrich & Schlessinger, 1990) make it potentially an
excellent target for antibody directed therapy (Mendelsohn,
1989). Ideally, the antibody of choice would have the ability
first to inhibit cell growth by blocking growth factor-receptor
interaction and second to activate complement and recruit
host effector cells to bring about tumour cell destruction.
Although a number of mouse monoclonal antibodies
(mAbs) have been developed in the last decade using the
A431 cell receptor as immunogen (e.g. Schreiber et al., 1981;
Waterfield et al., 1982; Sato et al., 1983; Livneh et al., 1986;
Murthy et al., 1987; Fendly et al., 1990; Pellegrini et al.,
1991) only a few have either of the desired properties. Mouse
antibodies are less effective in activating human effector func-
tions than are rat antibodies of the IgG2b isotype (Hale et
al., 1985; Dyer et al., 1989). Furthermore, the effectiveness of
monoclonal antibodies in harnessing host effector functions
depends not only on the isotype of the antibody but also,
importantly, on the particular epitope bound on the target
antigen. For this reason it is necessary to search for an
antibody that maximises the biological and immunological
functions.
We have reported (Modjtahedi, et al., 1992) the prepara-
tion and properties of ten rat mAbs that bind to three
distinct epitopes (A,B,C) on the external domain of the
EGFR using as immunogen the human squamous cell car-
cinoma HN5. While all of the mAbs against epitopes B and
C blocked the binding of EGF and TGFa to the receptor on
a number of squamous carcinoma cell lines the antibodies
against epitope C were an order ofmagnitude better than the
others at inhibiting cell growth. The best antibody, ICR16,
inhibited completely the growth of HN5 cells in vitro at
antibody concentrations above 1 nM. However, none of the
antibodies was of the IgG2b isotype and therefore would not
be expected to interact efficiently with the host immune
effector functions in rat, mouse or man. Since our intention
is to test the effectiveness of antibodies in the clinic we report
here the preparation of a second series of antibodies using as
immunogen the EGFR over-expressing breast carcinoma
MDA-MB 468 (Filmus et al., 1985) searching particularly for
IgG2b antibodies with growth inhibitory properties.
Materials and methods
Cell lines
The following cell lines were kindly provided by Dr M.J.
O'Hare: (a) carcinomas with > 106 receptors/cell, LICR-
LON-HN5, LICR-LON-HN6 and LICR-LON-HN15 (head
and neck), A431 (vulval), MDA-MB 468 (breast); (b) cells
with <i10 receptors/cell, EJ (bladder), SKOV3 (ovarian)
and SKBR3 (breast). SKOV3 and SKBR3 also overexpresses
the c-erbB2 product at a level some tenfold greater than the
EGFR. The EGFR expressing A172 (glioblastoma) and
A549 (lung) cell lines were obtained from ECACC, Porton
Down. MDA-MB 435, a human breast adenocarcinoma
which does not express detectable levels of the EGFR and
the mouse EGFR expressing Ca6 cells were provided by Dr
S.A. Eccles. Cells were cultured routinely in Dulbecco's
modified Eagle's medium (DMEM) supplemented with 10%
fetal calf serum (FCS) and the antibiotics penicillin, strepto-
mycin and neomycin.
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Production and testing ofanti-EGFR monoclonal antibodies
Two immunisation protocols were performed with cells
harvested from confluent flasks by trypsinisation. In the first,
CBH/cbi rats were immunised via their Peyer's patches with
4 x 106 MDA-MB 468 cells contained in 1001il of phosphate
buffered saline, pH 7.2. The rats were rechallenged via the
same route and with the same number of cells two weeks
later and again 4 weeks after the primary immunisation.
Alternatively, the rats were immunised at five sites (4 x s.c.
and 1 x i.p.) with a total of 107 MDA-MB 468 cells con-
tained in PBS then rechallenged two weeks and six weeks
later via the-same route with 3 x 106 cells. Lymphocytes were
prepared for fusion from either mesenteric nodes or spleens
three days after the last immunisation.
Hybridomas were prepared (Dean et al., 1984) by fusing
108 lymphocytes with 5 x 107 Y3 myeloma cells. Between
eight to twelve days later the wells were screened for the
presence of antibodies that inhibited the binding of 251I-EGF
(I04 c.p.m./well) to MDA-MB 468 or EJ cells that had been
grown to confluence in 96-well plates. Colonies from positive
wells were picked individually, grown up and cloned twice by
limiting dilution. The isotype ofeach mAb was determined as
described previously (Styles et al., 1990).
Control antibodies used in this investigation
MAb ALN/11/53 is directed against a membrane antigen on
the rat sarcoma HSN (Dean et al., 1984), ICR12 (Styles et
al., 1990) and ICR55 are directed against distinct epitopes on
the extracellular domain of the c-erbB-2 p185. Antibodies
ICRIO and ICR16, prepared against the receptor on HN5
cells (Modjtahedi et al., 1992), were used as positive controls.
Purification ofmonoclonal antibody
Antibodies were precipitated from culture supernatant or
ascites (prepared in athymic rats) with (NH4)2SO4 to 45% of
saturation. MAbs of the IgG2a and IgG2b isotype were
purified by ion-exchange chromatogrphy on DE52 cellulose
(Whatman Ltd., Maidstone, Kent). IgA and IgGl antibodies
were purified by affinity chromatography on MARKI (Bazin
et at., 1984) covalently coupled to Sepharose 4B. All prepara-
tions were dialysed extensively against PBS, filter sterilised
and stored frozen.
Radioiodination ofproteins
Monoclonal antibodies, mouse or human EGF (Col-
laborative research, Waltham, Mass.) or human recombinant
TGFa (Boehringer Mannheim, Germany) were labelled,
using the lodogen procedure (Fraker and Speck, 1978), with
Iodine-125 (Na'25I, Amersham International) to a specific
activity of 10 lCi tg-1'.
Epitope determination by competitive radioimmunoassay
Triplicate samples (501l) of doubling dilutions of each
purified mAb (50j.gml-' initial concentration) in DMEM-
3%FCS or neat culture supernatant (ICR65), were mixed
with an equal volume containing 2.5-3.0 x 104 cpm/well of
the '251-labelled mAb, '25I-EGF or '25I-TGFx. Controls con-
taining medium alone or ALN/11/53 were set up in the same
way. Aliquots of 90y of each mixture were transferred to
monolayers of MDA-MB 468 or EJ cells grown to
confluence in 96-well plates. After incubation for one hour
on ice the cells were washed three times with diluent, then
lysed in 1 M NaOH containing 1% sarkosyl and the bound
radioactivity determined in a Hydragamma spectrometer
(Oakfield Instruments Ltd, Oxford). Antibodies were con-
sidered to be in the same epitope cluster if they inhibited the
binding of each other to the cells by more than 80%.
Determination ofantibody affinity
Dissociation constants were determined from Scatchard plots
of binding of '25I-labelled antibodies to the EGFR receptor
isolated from HN5 cells as described by Modjtahedi et al.
(1992). Immunoreactivity, i.e. the proportion of radiolabelled
antibody that would bind antigen at infinite antigen excess,
was determined using a protocol similar to that described by
Lindmo et al. (1984).
Immunoprecipitation of35S-methionine-labelledproteins
The proteins of HN5, SKOV3 or A431 cells were radio-
labelled by incubation for 16-20 h with 35S-methionine
(200pCi/80 ml-1 flask containing 5 ml methionine-free
DMEM), and cell lysates were prepared using Triton-X 100
as described previously (Styles et al., 1990). Immunopre-
cipitates were made by incubating 1 ml aliquots of the radio-
labelled cell extracts with 50;d of Sepharose-linked rabbit/rat
Fab (5 mg ml-' gel) that had been incubated previously with
one of the specific rat/EGFR mAbs, ICR12 or ALN/11/53
(50tLg mAb/50 tl anti-Fab beads). 35S-methionine-labelled
truncated EGFR secreted into the culture supernatant by
A431 cells was immunoprecipitated in the same way. After
rotation overnight at 4°C the samples of gel were washed
four times in lysis buffer then analysed by SDS-PAGE on
7.5% reducing gels.
Effect ofantibody and/or TGFc on quiescent humanfibroblasts
DE532 cells (Flow laboratories) were seeded at 4 x 104
cells ml1' in DMEM containing 10% FCS and grown to
confluence in 24 well plates, then the medium was replaced
with DMEM containing 1% FCS. After 48 h in this medium,
50fil aliquots of mAb (25jgml-') and/or TGFa (5 ngml-l)
were added to quadruplicate wells and the cells were
incubated overnight at 37°C then pulsed for 6 h with 2fiCi/
well of 3H-thymidine. The acid insoluble radioactivity incor-
porated into DNA was determined in a liquid scintillation
counter.
Effect ofantibodies to the EGFR on growth oftumour cells in
culture
About 5 x 103 cells in 100j4 of DMEM containing 2% FCS
were seeded into each well of a 96-well plate. After incuba-
tion for 4 h at 37°C, 100ftl aliquots of dilutions of each mAb
(starting at 50gLg ml) were added in triplicate to the wells and
the cultures were incubated at 37°C. Controls were set up
that contained either medium alone or medium containing
dilutions of a control antibody (ALN/11/53). The cultures
were incubated for a further 3 to 10 days until the controls
incubated in medium alone were almost confluent and had
increased in number to a maximum of 5 x I04 cells per well.
All cells were fixed with 0.25% glutaraldehyde then washed
in water, air dried and stained with 0.5% methylene blue
(100 tll/well) for 15 min. After washing with tap water and
air drying, 200 tL of 0.33N HCI was added to each well and
the A620 of each supernatant was determined in a Titertek
Multiscan. To determine the initial number of cells present at
the start of treatment in each experiment, an extra plate was
set up and the cells were fixed 4 h after the start of incuba-
tion at 37°C. Growth as a percent of control was determined
from the formula:-
% growth = B-A x 100
C-A
Where A = A620 at start of experiment
B = A620 after treatment with antibody
C = A620 after incubation in medium alone
To investigate the effect of endogenous growth factors pres-
ent in FCS on the activity of the antibodies, experiments
were carried out using DMEM containing 2%, 5% or 10%
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Results
Production ofhybridomas
Five hybridomas (ICR60-64) producing mAbs that
specifically inhibited the binding of '25I-EGF to its receptor
were obtained from two fusions using mesenteric node cells
taken from rats immunised via the Peyer's patches with
MDA-MB 468 cells. Recently, a further antibody (ICR65)
has been obtained using spleen cells from a third immune rat
and all the results reported here with this antibody have been
obtained using culture supernatant. The effect of these mAbs
on the binding of '25I-EGF to the bladder carcinoma cell line
EJ, is presented in Figure 1. Three of these antibodies
(ICR61, ICR62 and ICR65) were of the IgG2b isotype
(Table I). Competitive assays showed (Table II) that
antibodies ICR60-64 bound to two distinct epitopes on the
external domain of the ECF receptor one of which (ICR62
and ICR63) was the same (epitope C) as that recognised by
antibodies ICRI1 and ICR16 produced previously against
the receptor on HN5 cells (Modjtahedi et al., 1992). ICR60,
ICR61 and ICR64 did not compete with any of the
antibodies raised against HN5 cells and were considered to
bind to an independent epitope (D) on the EGFR (Table I).
ICR65, however, competed with all the new antibodies
(Figure 2) for binding to the receptor suggesting that
epitopes C and D were adjacent. The immunoreactivity of
the antibodies tested varied from 31% (ICR61) to 74%
(ICR64, see Table I). The new antibodies were of high
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Figure 1 Inhibition of binding of '25I-EGF to the receptor for
EGF on EJ cells by mAbs: (@), ICR60; (U), ICR61; (A),
ICR62; (v), ICR63; (*), ICR64; (a), ICR65; (*), ALN/11/53.
Table I Rat monoclonal antibodies to the human EGF receptor
Immunogenl Epitope cluster Affinities Immuno-
antibody Isotype A B C D (nM) reactivity Reference
(a) HN5 Modjtahedi
ICR9 IgG2a + 3.5 53% et al (1992)
ICR1O IgG2a + 6.7 69%
ICRI1 IgG2a + 5.00; 1.2 68%
ICR14 IgG2c + 2.90; 70.0 73%
ICR15 IgG2a + 5.50; 68.0 33%
ICR16 IgG2a + 0.37; 3.7 49%
ICR28 IgA + N.D. N.D.
ICR29 IgA + N.D. N.D.
(b) MDAMB468 this work
ICR60 IgA + N.D N.D
ICR61 IgG2b + 0.25; 1.40 31%
ICR62 IgG2b + 7.50 69%
ICR63 IgG2a + 0.15 54%
ICR64 IgGI + 0.61; 1.80 74%
ICR65 IgG2b + + N.D N.D
N.D = Not determined.
Table II Effect of rat mAbs to the Human EGFR on the binding of 25I EGF
(A) or '25I TGFa (B) to human carcinoma cells
A
"25I EGF bound (% Control) to:
mAb Head and neck Lung Breast Brain Bladder
(78nM) (HN5) (A549) (MDA-MB468) (A.127) (EJ)
ICR60 48.7 27.4 8.5 22.0 30.0
ICR61 33.7 11.5 19.0 10.5 11.2
ICR62 23.4 9.5 18.6 16.7 12.9
ICR63 22.8 4.2 10.0 9.3 7.7
ICR64 24.2 10.1 4.9 9.2 5.4
ICR65 49.5 24.3 ND 22.6 8.5
B
125I TGFa bound (% Control) to:
mAb Head and neck Vulva Breast Bladder Ovarian
(156nM) (HN5) (A431) (MDAMB468) (EJ) (SKOV3)
ICR60 41.8 31.6 19.9 14.0 34.9
ICR61 31.3 25.8 12.9 10.4 6.9
ICR62 24.5 24.1 10.3 7.2 6.4
ICR63 38.3 24.1 12.5 4.6 20.3
ICR64 15.4 18.7 4.8 6.4 7.4
ICR65 33.4 25.8 9.4 5.6 4.3250 H. MODJTAHEDI et al.
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Figure 2 Competitive binding assays show that the rate
antibodies recognise two distinct epitopes on the external domain
of the EGFR. MAbs ICR60 (0), ICR61 (M), ICR62 (A),
ICR63 (V), ICR64 (*) and ICR65 (*) were competed with
'25l-ICR63 or '25l-ICR64 for binding to monolayers of EJ cells.
affinity and two of the Scatchard plots (ICR61, ICR64)
showed two affinities for binding (Table I).
All six antibodies inhibited the binding of EGF and TGFa
to the receptor present on five human tumour cell lines of
different origin (Table II) and as expected maximal inhibition
was observed with the cell lines (e.g. EJ and SKOV3) that
expressed lower levels of the EGFR. This result suggests that
most of the antibodies bind at or near to the ligand binding
site on the receptor. However, the antibodies did not bind to
the mouse EGFR since none of them inhibited the binding of
'25I-EGF to the mouse cell line Ca6 (data not shown).
The antibodies do not crossreact with theproduct ofthe
c-erbB-2 proto-oncogene
MAbs ICR60-ICR64 and ICR1O (positive control antibody
raised against EGFR on HN5 cells) all specifically
immunoprecipitated the 170 kDa EGFR from detergent ext-
racts of 35S-methionine-labelled HN5 cells whereas a control
antibody (ALN/11/53) did not (Figure 3). The mAbs also
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Figure 3 Autoradiographs of immunoprecipitates prepared from
35S-methionine-labelled cells, HN5 (top) or SKOV3 (bottom), and
run on 7.5% reducing gels. Immunoprecipitates were prepared
with mAbs to the EGF receptor (ICR1O, ICR60-64), the product
of the c-erbB-2 p185 (ICR12) or control antibody (ALN/11/53).
immunoprecipitated the EGFR from detergent extracts of
35S-methionine-labelled SKOV3 cells but not the 185 kDa
overexpressed product of the c-erbB-2 gene. The latter was,
however, precipitated from these extracts (Figure 3) by
antibody ICR12 (Styles et al., 1990). We conclude that none
of the antibodies tested (ICR60-64) crossreacted with the
c-erbB-2 gene product.
Effect ofantibody and or TGFc on proliferation ofhuman
fibroblasts
Both EGF and TGFa stimulate DNA synthesis in quiescent
human fibroblasts. We have investigated the effect of our
antibodies used alone or in combination with growth factors
on DE532 cells. The results, presented in Table III, show that
none of the antibodies alone could stimulate DNA synthesis
in these cells. All of the antibodies blocked TGFa stimulated
DNA synthesis; completely in the case of ICR61-ICR64, but
antibody ICR60 was less effectives. We conclude that all the
Table III Effect of anti-EGFR monoclonal antibodies, TGFo or both on DNA synthesis in quiescent human
foreskin fibroblasts (DE532)
3H-Thymidine incorporation (CPM)
TGFc ICR60 ICR61 ICR62 ICR63 ICR64 ALN115/3 NO
(ngml-') 25 tLgml-' 25fLgmlt' 25figml-' 25 tgmt' 25jLgmlt' 25 lgml'I Antibody
0 240 201 247 250 199 223 316
5 770 189 190 308 221 1556 1755
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antibodies acted as antagonists of TGFa. Similar results were
obtained when EGF was used instead of TGFa (data not
shown).
The mAbs inhibit the growth oftumour cells that overexpress
the EGFR
The growth of HN5 and HN6 cells was inhibited completely
when cultures were incubated with the antibodies to the
EGFR at a concentration of 25jigml-I or greater (Table
IV). When tested at lower concentrations, some of the mAbs
were found to be more effective than others (Figure 4) and
the order of effectiveness for inhibition of growth of HN5
cells was ICR64 (IgGl)>ICR62 (IgG2b)>ICR63 (IgG2a)
>ICR60 (IgA) , ICR61 (IgG2b). Antibodies ICR60-64
were also tested for their effect on the growth of a number of
other tumour cell lines including those (A431, HN15, MDA-
MB 468) with high levels of expression of the EGFR, or
those (EJ, SKOV3, SKBR3) with lower levels of EGFR
expression (<1 x 105 receptors/cell) or cells that did not
express detectable levels of the EGFR (MDA-MB 435). The
results of this comparative study using media containing 2%
FCS are presented in Table IV. They show that growth of
the cell lines with high level expression of the EGFR was
inhibited by all of the antibodies tested. At a concentration
of 156 nM, however, the antibodies were without effect on the
growth of SKBR3, SKOV3, EJ or MDA-MB 435 cells.
To investigate if endogenous growth factors present in
FCS affected the activity of the anti-EGFR antibodies,
experiments were repeated using HN5 cells incubated in
media containing 5% or 10% FCS. Only a small shift in
baseline (10%) was observed with these antibodies (cf ICR64,
Figure 5) even at the highest concentration of FCS used and
we conclude that at the concentration present in FCS such
growth factors had little effect on the growth inhibitory
activity of the mAbs.
Table IV Effect of mAbs to the EGF receptor on the growth of
tumour cells in medium containing 2% foetal calf serum
Growth (% medium control) of:
mAbs
(156nM) HN15 HNS HN6 A431 MDA-MB468
ICR60 39.6 2.7 ND ND ND
ICR61 32.4 -1.0 -6.7 66.1 40.1
ICR62 18.3 1.1 -7.1 65.3 32.8
ICR63 -0.1 -1.4 3.4 71.8 67.0
ICR64 22.8 0.1 0.0 ND 39.7
No effect on SKBR3, SKOV3 and EJ cells.
ND = Not determined
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Figure 4 Influence of antibodies to the human EGFR on the
growth of HN5 cells in DMEM containing 2% FCS. (A),
ICR60; (V), ICR61; (*), ICR62; (*), ICR63; (0), ICR64; (U),
control ALN/11/53.
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Figure 5 Influence of the concentration of foetal calf serum on
the inhibition of growth of HN5 cells by antibody ICR64. FCS
concentration: (-), 2% (A), 5%; (V), 10%).
While the head and neck carcinomas HN5, HN6 and
HN15 were the most sensitive to antibody induced inhibition
of growth, A431 and MDA-MB 468 were less susceptible.
A431 cells have been reported to secrete large amounts of a
truncated form of the receptor (Weber et al., 1984) and this
may have influenced the interaction of the rat antibodies with
the transmembrane receptor.
The mAbs bind to the truncated EGFR secretedby A431 cells
When '251I-labelled mAbs (2.2-2.5 x I04) were mixed with
culture supernatant obtained from A431 cells the binding of
antibodies ICR60-64 to EJ cells was abolished (Table V).
Also, the 100 kD truncated receptor was precipitated when
cell free supernatants from "5S-methionine labelled A431 cul-
tures were immunoprecipitated with mAbs ICR16 and ICR64
(Figure 6) but not when the control antibodies (ALN/1 1/53,
ICR12, ICR55) were used. Clearly, with tumours like A431,
the presence of large amounts of truncated receptor may
decrease the effective dose of antibody reaching the tumour
cells.
Discussion
In this paper we describe the production and some of the
properties of six new rat monoclonal antibodies directed
against the human EGF receptor. Our results show that these
antibodies have the following properties, they: (a) bind with
high affinity to two distinct epitopes on the extracellular
domain of the human EGFR, (b) do not cross-react with the
related product of the c-erbB-2 proto-oncogene, (c) prevent
the binding of exogenous growth factors to the receptor, (d)
inhibit the growth stimulatory effects of EGF and TGFa on
human fibroblasts and (e) inhibit the growth of human
tumour cell lines overexpressing this receptor. Three of these
antibodies are of the IgG2b isotype (ICR62, epitope C;
ICR61, epitope D and ICR65, epitopes C and D). While all
of the antibodies stained frozen sections of cells overexpress-
ing the EGFR, none was found to bind the fully reduced
Table V Effect of supernatant from human epidermoid carcinoma
cell line (A431) on the binding of 25I anti-EGF receptor mAb to the
EGF receptor on EJ cells. Each value is the mean of triplicate
samples
125I Antibody Bound (cpm).
Treatment ICR61 ICR62 ICR63 ICR64
A431 supernatant 88 92 165 139
Controf medium 1200 700 1289 2567252 H. MODJTAHEDI et al.
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Figure 6 Autoradiographs of immunoprecipitates of 35S-
methionine labelled EGFR and truncated EGFR secreted by
A431 cells run on 7.5% reducing gels. Track A: ICR16; track B
ICR64; track C ICR12; track D ICR55; track E ALN/11/53;
track F medium control.
receptor in Western blots nor did they bind to formol-saline
fixed paraffin embedded tissues (data not shown). We conc-
lude that mAbs ICR60-64 all recognise conformational
determinants on the receptor.
During the last decade a number of laboratories have
generated antibodies against the human EGFR with a view
to their use in structural studies on the receptor or for
clinical applications in oncology. In most cases the antibodies
were raised in mice against the EGFR on the vulval car-
cinoma cell line A431. Because the A431 receptor also con-
tains the blood group A antigen, many of the antibodies
produced crossreact with this normal antigen limiting their
use for diagnostic or therapeutic purposes (see review by
Sato et al., 1987).
As in A431 cells, the receptor for the EGFR is over-
expressed on the surface of MDA-MB 468 cells but, unlike
A431 cells, the gene for the EGFR is not rearranged (Filmus
et al., 1987). Our aim has been to produce rat monoclonal
antibodies that bind to different epitopes on the external
domain of the human receptor for EGF so that we can
identify the best epitope to target for growth inhibition as
well as the best antibody for harnessing host immune effector
functions. For this reason we have used rats as our source of
antibodies rather than mice because some rat antibodies of
the IgG2b isotype interact very efficiently with the effector
arm of the human immune system (Dyer et al., 1989).
We have reported (Modjtahedi et al., 1992) that rat mAbs
raised against the head and neck carcinoma cell line LICR-
LON-HN5 bound with high affinity to one of three distinct
epitopes (A,B,C) on the EGFR but none were of the IgG2b
isotype. Outstanding, in terms of inhibition of growth of
HN5 cells, were antibodies ICR11 and ICR16 both of which
were directed against epitope C. Here we report that two out
of a further six mAbs raised against the EGFR on MDA-
MB 468 cells also bound to epitope C and one of these was
an IgG2b (ICR62) with good growth inhibitory properties in
vitro. Interestingly, three of the four other mAbs recognised a
new epitope (D) on the EGFR and one of these mAbs
(ICR61)iwas an IgG2b. Lastly, antibody ICR65, which is of
recent production, is also an IgG2b and this mAb cross-
reacted with both epitopes C and D. The other properties of
this antibody are currently being determined.
The isolation of three antibodies against a novel epitope
on the EGFR was surprising since no antibodies of this type
were obtained in nine separate fusions when HN5 cells had
been used a immunogen. Clearly, this resulted from the use
of a different source of EGFR as immunogen (MDA-
MB468) which in turn led also to the isolation of three mAbs
of the IgG2b isotype. These findings reinforce our view that
it is essential to use different source of immunogen to obtain
as diverse a population of antibodies (epitope/isotype) from
which the best antibody for clinical use can be selected.
In terms of biological activity, antibody ICR61 was the
least effective of the new antibodies and complete inhibition
of growth of HN5 cells was only obtained at a concentration
of 20 nM which was an order of magnitude higher than that
required with ICR62 or ICR64, which inhibited completely
the growth of these cells at a concentration of 2.4 nM. Indeed
ICR64 was one of the best of all the rat mAbs tested and it
equalled ICR16 (Modjtahedi et al., 1992), in terms of its
capacity to block the binding of EGF to its receptor and to
inhibit the growth of HN5 cells in vitro. We conclude that
both epitopes C and D constitute suitable targets for
antibody directed therapy.
The antibodies very effectively inhibited the growth in vitro
of three different head and neck carcinoma cell lines. They
were less effective, however, when tested on A431 or MDA-
MB 468 cells. The A431 cell line is aberrant in that it secretes
large amounts of a truncated form of the EGFR (Weber et
al., 1984) to which all of the rat antibodies bind. This soluble
EGFR may therefore reduce the effectiveness of the mAbs at
inhibiting growth of this cell line. Furthermore, it has been
shown that, in addition to overexpression of the EGFR, both
A431 and MDA-MB 468 cells produce TGFax constitutively
(Derynck et al., 1987; Ennis et al., 1989). High level secretion
of this ligand by these cells may also reduce the effectiveness
of the antibodies in vitro by competing with them for binding
to the receptors and this aspect is under investigation.
Currently, we are testing some of the antibodies for their
activity in vivo against xenografted human tumours growing
in athymic mice and the results obtained are very encourag-
ing. These experiments are described in the accompanying
paper and show that ICR62 and ICR64 were effective at
eliminating the tumours when given at the time of tumour
cell inoculation. ICR62 was also effective in inducing regres-
sion of established tumours.
We believe that this new generation of rat mAbs which
bind with high affinity to the EGFR, block ligand-receptor
interaction and inhibit the growth of squamous cell car-
cinomas overexpressing the receptor have potential for
clinical application.
This work was supported by a Programme Grant from the Cancer
Research Campaign, London.
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